When should weekly intravenous alpha‑1 antitrypsin (A1AT) augmentation therapy be initiated, and what is the recommended dosing regimen?

Alpha-1 Antitrypsin IV Weekly Treatment

Initiate weekly intravenous alpha-1 antitrypsin augmentation therapy at 60 mg/kg body weight for patients with severe A1AT deficiency (<11 mmol/L or <0.57 g/L), documented SERPINA1 deficiency genotypes, CT-confirmed emphysema, FEV1 <80% predicted, who are never-smokers or former smokers (smoke-free ≥6 months), and receiving optimal COPD therapy. 1

Dosing Regimen

• Administer 60 mg/kg body weight intravenously once weekly at a rate not exceeding 0.2 mL/kg body weight per minute, adjusted based on patient tolerance 2, 1
• This dosing maintains serum A1AT levels above the protective threshold of 11 mmol/L (0.57 g/L) at trough (immediately before the next infusion) 1, 3
• Always use a 5 micron in-line filter (minimum diameter 32 mm) during infusion 2
• If adverse events occur, reduce the infusion rate or interrupt until symptoms subside, then resume at a tolerated rate 2

Mandatory Pre-Treatment Requirements

Diagnostic Confirmation

• SERPINA1 gene sequencing is mandatory—not just serum levels—because over 300 genetic variants exist and some produce normal circulating levels but dysfunctional protein 4, 1
• Serum A1AT level must be <11 mmol/L (<0.57 g/L) to meet severe deficiency threshold 1
• High-resolution CT chest must document emphysema presence 4, 5
• Post-bronchodilator spirometry must show FEV1 <80% predicted 1, 4

Smoking Status Verification

• Patient must be a never-smoker or former smoker who has been completely smoke-free for at least 6 months before therapy initiation 4, 5
• Continued smoking negates the protective benefits of augmentation therapy, making treatment futile 4

Baseline COPD Management

• Patients must already be on optimal conventional COPD therapy including inhaled bronchodilators, inhaled corticosteroids (if indicated), preventive vaccinations (influenza, pneumococcal), and supplemental oxygen if needed 1, 4
• Augmentation therapy is NOT a replacement for standard COPD management but an adjunctive therapy for the underlying A1AT deficiency 4

Additional Laboratory Testing

• Screen for IgA deficiency with anti-IgA antibodies (absolute contraindication) 2, 4
• Obtain baseline liver function tests (AST, ALT, bilirubin, alkaline phosphatase), particularly in elderly patients 4
• Document Hepatitis A and B vaccination status 4

Evidence for Efficacy by Disease Severity

• Strongest evidence exists for patients with FEV1 31-65% predicted (moderate emphysema): yearly FEV1 decline of -53 mL in treated versus -75 mL in untreated groups (p<0.02) 1, 5
• The NHLBI Registry demonstrated mortality benefit (OR 0.79, p<0.02) and slowed FEV1 decline specifically in the subgroup with FEV1 35-49% predicted 4, 5
• The RAPID trial showed significant slowing of CT lung density decline over 2 years, with extrapolation estimating 6 years longer survival before death or transplantation if therapy continued 1
• Evidence quality: high for CT lung density preservation, very low for mortality benefit 1

Critical Pitfalls to Avoid

• Do not initiate therapy based solely on A1AT deficiency diagnosis—the presence of emphysema on CT scan is mandatory 5, 4
• Do not rely solely on serum A1AT levels for diagnosis—genetic confirmation with SERPINA1 sequencing is required because some variants produce normal levels but dysfunctional protein 4, 1
• Do not use augmentation therapy for A1AT deficiency-related liver disease, necrotizing panniculitis, or ANCA-positive vasculitis—it is indicated only for lung disease 4
• It is unknown whether augmentation therapy benefits patients without impaired FEV1 or whether earlier therapy would fully prevent lung function decline 4

Absolute Contraindications

• IgA deficiency with antibodies against IgA 2, 4
• History of anaphylaxis or severe systemic reaction to A1AT products 2
• Active smoking 4
• Lack of documented emphysema on imaging 4

Safety Profile

• Augmentation therapy has a favorable safety profile with rare adverse reactions 5, 6
• Most common adverse reactions are headache and upper respiratory infection 2
• Mild reactions (fever, chills, dyspnea) and anaphylactic reactions are rare with complete recovery 5
• May carry theoretical risk of transmitting infectious agents including viruses, vCJD, and CJD 2

Conditions NOT Indicated for Therapy

• Patients with MS phenotype (heterozygous M/S) typically maintain A1AT levels above the protective threshold and do not qualify for augmentation therapy 7
• Patients without CT-documented emphysema, even with confirmed A1AT deficiency 4, 5
• Patients with FEV1 ≥80% predicted (benefit not established) 1